Inflammatory Bowel Diseases · 2022 · 39 citations · 24 references
MedicineImmunologySurgeryGastrointestinal OncologyImmunotherapyInflammationCrohn Disease PharmacotherapyGastrointestinal InflammationInflammatory Bowel DiseaseMucosal InflammationCohort Study InvestigationInflammatory Bowel Disease TherapyPostoperative ProphylaxisPostoperative Recurrence PreventionRecurrenceSurgical Bowel ResectionTumor Necrosis Factor TherapyUstekinumab Therapy
BACKGROUND: Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). METHODS: We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (≥ i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab). RESULTS: We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis. CONCLUSION: Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
24
Predictability of the postoperative course of Crohn's disease
P. Rutgeerts, Karel Geboes, G. Vantrappen et al. · Gastroenterology · 1990 · 1.8K citations
Crohn's disease management after intestinal resection: a randomised trial
Peter De Cruz, Michael A. Kamm, Amy L. Hamilton et al. · The Lancet · 2014 · 607 citations
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro, Wolfgang H. Schraut, Leonard Baidoo et al. · Gastroenterology · 2008 · 602 citations